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Phosphodiesterase Type 5 (PDE5) inhibitors are cardioprotective against 
ischemia/reperfusion (I/R) injury.  However, it remains uncertain if I/R affects PDE5.  We 
hypothesized that generation of reactive oxygen species (ROS) during I/R leads to 
upregulation of PDE5, which contributes to pathological changes following acute 
myocardial infarction (AMI).  Adult male ICR mice were subjected to 30 minutes of in 
vivo or ex vivo I/R.  To examine the role of ROS, a subset of hearts were perfused with 100 
µM hydrogen peroxide (H2O2).  Expression and activity of PDE5, pPDE5, and cGMP-
xvii 
dependent protein kinase (PKG) were measured by Western blots and spectrophotometric 
assay.  The results show that ischemia and I/R significantly increased expression of PDE5.  
H2O2 had no effect on PDE5 expression and activity but significantly increased PKG 
activity.  We conclude that acute cardiac ischemia or I/R upregulate PDE5 independent of 
oxidant stress in the heart. 
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Introduction 
 
1.1 Coronary Heart Disease 
 
 Coronary heart disease (CHD) is the failure of the coronary circulation to supply 
adequate blood to the cardiac muscle and surrounding tissue.  The American Heart 
Association has determined CHD, the cause of heart attacks and angina, will be the single 
leading cause of death in the United States this year just as it has been for the past sixty 
years, since 1950.  Approximately 425,500 people a year now die of CHD which is nearly 
75% of all deaths.  In all, about every 25 seconds an American will suffer a coronary event, 
and about every minute someone will die from one such attack.  In 2010, CHD will cost 
the United States $316.4 billion.  This total includes the cost of health care services, 
medications, and lost productivity.1  Taken together, these indicators constitute a rather 
bleak prognosis regarding the overall cardiovascular health of our country’s population and 
indicate the urgency with which new medical therapies are needed in order to combat CHD 
and reduce its enormous national impact.  
 As previously mentioned, a heart attack, or acute myocardial infarction (AMI), is a 
severe condition caused by CHD.  Every year about 785,000 Americans have a first AMI 
and 470,000 who have already had one or more will have another.  All together AMI 
affects an estimated 1.5 million people in the United States annually and is a major cause 
of mortality and morbidity worldwide.  Over half of the patients with AMI die within one 
2 
hour of the event.1  AMI occurs when there is a sudden occlusion of an artery supplying 
blood to cardiac muscle, or myocardium, depriving the area of blood and oxygen and 
causing dramatic changes in the cellular metabolism and function within this tissue.  The 
occlusion leading to AMI is usually caused by a buildup of atheromatous plaques on the 
walls of the arteries that supply the myocardium.  These plaques consist largely of 
macrophage cells containing cholesterol and fatty acids, calcium, and a variable amount of 
fibrous connective tissue.  The resultant lack of blood flow and oxygen is called ischemia 
and if maintained for more than a few minutes, there is a loss of contracting myocardium 
in the affected area and a resultant increase in the workload on the remaining viable 
myocardium.  This cardiac overload causes increased energy utilization and a supply-
demand imbalance, which lead to cellular necrosis and apoptosis.  This subsequently leads 
to remodeling and worsening of left ventricular function, and eventually heart failure.2  
Since the division of surrounding myocytes cannot replace those that have died from 
necrosis and apoptosis, preservation of the myocardium viability after ischemia has 
become a major target for therapeutic research.3 
 
1.2 Ischemia/Reperfusion Injury 
 
 Following the occurrence of a detrimental occlusion of a coronary artery, it was 
shown in 1983 that reperfusion of the vessel was vital to protecting the ischemic 
myocardium and salvaging the remaining viable tissue.4  Since that time, the advent of 
therapies such as thrombolysis, anti-platelet, and primary angioplasty have provided a 
means to reestablish coronary blood flow in the clinical setting.  Yet paradoxically, the 
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reperfusion therapy itself, following ischemia, results in cardiomyocyte death; an inherent 
phenomenon termed ischemia/reperfusion (I/R) injury. 
Cell death following I/R has been reported to have features of apoptosis, necrosis, 
and autophagy.  Apoptosis, or programmed cell death, typically occurs via activation of 
caspases that cleave DNA and other cell components.  Caspase 9 has been reported to be 
activated during ischemia, whereas caspases 8 and 9 are activated during reperfusion.5  A 
number of studies have reported that addition of caspase inhibitors reduces infarct size, 
suggesting an important role for caspase activation in I/R injury.5-7  Necrosis, or traumatic 
cell death, is characterized by cell swelling leading to irreversible rupture of the plasma 
membrane, release of cytosolic components, and finally an inflammatory response, which 
is an important component of I/R injury.  The release of troponin and creatine kinase that 
occur during I/R are likely due to necrosis.  A rise in cytosolic free Ca2+ as well as the 
production of reactive oxygen species (ROS) has been consistently observed in ischemia 
and early reperfusion.  An increase in Ca2+ and ROS can lead to activation of an inner 
mitochondrial large-conductance channel known as the mitochondrial permeability 
transition pore (MPTP), causing loss of ATP and mitochondrial function.  If a large 
number of mitochondria in a cell undergo MPTP, the cell will lose the capacity to make 
ATP and ion homeostasis, resulting in necrosis.  Finally autophagy is a physiological 
mechanism that is used to remove damaged organelles, such as mitochondria or 
endoplasmic reticulum, and extensive autophagy can cause cell death.  It has been shown 
that a decrease in a primary protein mediator of autophagy, beclin1, reduces I/R-mediated 
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autophagy and myocyte death.8  Additionally, an increase in Ca2+, which as stated occurs 
during ischemia, has been shown to increase autophagy.9 
 Ultimately, death following I/R injury appears to be a mixture of apoptotic, 
necrotic, and autophagy cell death, and it can have features of all three.  The distinction 
between the modes of death may not be simple, since recent data suggest that all three 
forms can be regulated and are interrelated.10,11  The primary issue is that cell death during 
I/R appears to be an active process, causing rapid disruption of heart tissue as shown by the 
release of certain cytosolic enzymes and changes in the microscopic structure of the 
myocytes.  Although the restoration of blood flow proved to be crucial to reduce infarct 
size 4, the contradiction of reperfusion injury presents a clinical challenge in finding 
therapeutic strategies to limit and reduce I/R insult, thus preserving heart function. 
 
1.3 Ischemic and Pharmacological Preconditioning 
In 1986, a phenomenon called ischemic preconditioning (IP) was discovered 
involving brief episodes of ischemia applied to the myocardium that would consequently 
protect the tissue from subsequent, more prolonged periods of ischemia.12  This incredibly 
innovative finding marked the beginning of a new field of research aimed at utilizing this 
phenomenon in the protection of the human heart from ischemic heart disease.  The 
cardioprotective effects of IP have been shown to occur in two different phases or 
“windows”.  The early phase, referred to as “classic” preconditioning, is primarily 
mediated by activation of signaling pathways and posttranslational modification of 
proteins.  It develops immediately after the IP maneuver and disappears within 1-2 
5 
hours.13,14  The later phase, referred to as the “delayed” window of preconditioning, is 
largely mediated by gene induction and protein synthesis.  It develops 12 hours later and 
lasts up to 96 hours.15-18  Both phases of IP have been shown to reduce infarct size, 
contractile dysfunction, arrhythmias, generation of lactate, and rate of fall in ATP.19-21 
Over the past 20 years, a great deal has been learned about the signaling pathways 
activated by IP and the cellular basis for its protection.  The proposed IP mechanisms 
include the release of endogenous mediators (such as adenosine, norepinephrine, opioids, 
free radicals, and bradykinin),22-26 activation of G protein-coupled receptors and the 
phosphatidylinositol 3-kinase (PI3K) pathway (and subsequent downstream targets such as 
protein kinase B [Akt], protein 70S6 kinase [p70S6K], protein kinase C [PKC], and 
extracellular signal-regulated kinase [ERK]),27-31 opening of mitochondrial KATP 
channels,32,33 and synthesis of cytoprotective proteins (including endothelial nitric oxide 
synthase [eNOS], inducible nitric oxide synthase [iNOS], cyclooxygenase-2, and heat 
shock protein 70).21,34-36 
A number of pharmacological activators of IP mechanisms have been given 
exogenously to mimic the observed cardioprotective effects.  These include adenosine 
receptor agonists, nitric oxide donors, bradykinin, anisomycin, cobalt chloride, and 
diazoxide; nevertheless, due to the lack of safe and effective drugs, none of the activators 
have been translated into clinical use.37  Our laboratory has been at the forefront of this 
field of research and, over the course of the last 8 years, a pioneer in inventing the concept 
of pharmacological preconditioning with selective phosphodiesterase type 5 (PDE5) 
inhibitors.  We have shown that drugs such as sildenafil (Viagra), vardenafil (Levitra) and 
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tadalafil (Cialis), which are known to enhance erectile function in men, also induce a 
powerful cardioprotective effect against I/R in rabbit and mouse hearts,38,39 myocardial 
ischemia-induced heart failure,2 and doxorubicin-induced cardiomyopathy in mice.40  In a 
series of publications, our laboratory has shown that this preconditioning-like 
cardioprotective effect against I/R involved upregulation of eNOS and iNOS, activation of 
PKC/ERK, opening of mitochondrial KATP channels, and attenuation of apoptosis by 
increasing the B-Cell Lymphoma-2 (Bcl2)/ Bcl-2–associated X protein (bax) ratio.38,39,41-43  
Still, as diverse as these mechanisms are, none has shown a direct involvement of PDE5 or 
relate to the known pharmacological action of sildenafil on inhibition of PDE5. 
 
1.4 Phosphodiesterase Type 5 
The intracellular second messengers cyclic adenosine 3’,5’-monophosphate 
(cAMP) and cyclic guanosine 3’,5’-monophosphate (cGMP) both serve vital roles in 
cardiovascular regulation by influencing function, gene expression, and morphology.  
cAMP is a mediator of many effects of epinephrine on the heart and other tissues while 
cGMP mediates nitric oxide (NO) and natriuretic peptide (NP) action.44-53  In 1958 cAMP 
was first discovered and this report was soon followed by that of cGMP in 1963.54,55  The 
search was then on for researchers to quickly identify enzymes that specifically hydrolyzed 
these messengers.  Eventually, 11 different 3’,5’-cyclic nucleotide phosphodiesterase 
(PDE) isoenzyme families (PDE1-PDE11) were identified and grouped according to their 
ability to hydrolyze cAMP and cGMP to the linear 5’-nucleoside monophosphates AMP 
and GMP, respectively.  This reaction is highly exothermic (> 10 kcal/mol), making it 
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essentially irreversible in the cell.56,57  Thus, by producing inert molecules and destroying 
the second messenger activity of cyclic nucleotides, PDEs play critical roles in a wide 
range of physiological and pathological processes.   
PDE5 was originally characterized in the context of an unidentified binding protein 
for cGMP and not as a PDE.58  Early descriptions noted a high-affinity cGMP-binding 
protein present that did not comigrate with cGMP-dependent protein kinase (PKG) 
activity, and at that time PKG was the only known high-affinity binding protein for cGMP.  
Within a few years, PDE5 was identified, isolated, and characterized from platelets and 
later lung.59-61  It was discovered to be functionally specific for cGMP hydrolysis along 
with the presence of high affinity-binding sites for cGMP.  At the time, it was initially 
thought that PDE5 might be related to the already well understood, light sensitive, cGMP-
selective PDE found in the eye, which is now known as phosphodiesterase type 6 (PDE6).  
Both enzyme families selectively used cGMP compared with cAMP as substrate, both 
bound cGMP with high affinity, both were inhibited by many of the same agents, and both 
had a very similar size.  However, differences in Vmax activities and the lack of regulation 
of PDE5 by light suggested that they might be different PDEs.  So there existed a 
continuing confusion in the scientific literature regarding the molecular identity of the 
cGMP-specific PDEs and PDE5 was originally labeled as the “cGMP-binding, cGMP-
specific PDE.”  The issue was finally resolved when the bovine lung cGMP-binding PDE 
was cloned, expressed, and sequenced.62  It was only upon comparison with the previously 
published PDE6 sequences that it was entirely clear PDE5 was a distinct gene product.63   
8 
Presently, PDE5 is now known to be dimeric with each monomer approximately 90 
to 100 kD in size, depending on species.  The carboxyl terminal portion contains the 
hydrolyzing catalytic domain of ~230 amino acids, encompassing two zinc-binding motifs 
and a catalytic cGMP binding site.  The amino terminal portion contains two allosteric 
cGMP binding sites of ~90 amino acids each and at least a portion of the dimerization 
domain.  These N-terminus binding sites are today called regulatory GAF domains of the 
enzyme, an acronym derived from the names of the first three classes of proteins 
recognized to contain these sequences, i.e., cGMP-binding PDEs, Anabaena adenylyl 
cyclase, and Escherichia coli Fh1A.64  The two GAF domains (GAF-A and GAF-B) are 
highly homologous, but cGMP binding occurs only to the GAF-A domain (KD < 40 nM) of 
PDE5.65  Cyclic nucleotide binding to this domain is greater than 100-fold selective for 
cGMP over cAMP, 65 and it has been shown that the allosteric binding of cGMP to the 
GAF-A domain stimulates enzyme catalytic activity about 10-fold, while blockage of this 
allosteric binding causes inhibited activity.66  Moreover, the affinity of this site for cGMP 
is increased by phosphorylation of nearby serine 92, which is just adjacent to the GAF-A 
domain, via PKG thereby stabilizing the activated form of PDE5.67,68  Since the original 
cloning of the PDE5 cDNA, only one PDE5 gene has been discovered to date, PDE5A, 
although 3 variants of the PDE5A mRNA and protein have been identified under the 
control of differentially regulated promoters.69-71  PDE5A1, PDE5A2, and PDE5A3 differ 
at their N-terminal regions, and all 3 have unique first exons followed by a common 
sequence of 823 amino acids.  While it has not been proven, it is postulated that the 
different promoters for the PDE5 isoforms allow differential control of PDE5 gene 
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expression and provide a mechanism for longer term regulation than just the allosteric 
binding or phosphorylation previously mentioned.   
Interestingly, despite it being one of the first of the 11 PDE families found to be 
cGMP specific, PDE5 received little notoriety or attention until studies discovered its role 
as a regulator of vascular smooth muscle tone.72-74  By the mid 1980’s, pharmacologists at 
Pfizer research laboratories were working on an antihypertension drug and postulated that 
a selective cGMP PDE inhibitor might relax arteries and lower blood pressure by 
augmenting intracellular cGMP.  In screening for agents that inhibited cGMP hydrolysis 
but not cAMP, they found a cGMP PDE selective agent, UK-92 480, which was first 
targeted clinically at angina pectoris.  The tests proved to be disappointing, with very little 
cardiovascular impact, however patients reported “side effects” at high doses, which 
included penile erections.  Pfizer shifted its indication to treatment for erectile dysfunction 
and sildenafil (Viagra) was created in 1998 as the first isozyme-selective PDE inhibitor in 
wide clinical use.  This “urological detour” away from investigating direct cardiovascular 
applications of PDE5 inhibition helps to explain why it took considerable time before 
focus was diligently applied to PDE5 with respect to cardiovascular disease and regulation.   
 
1.5 PDE5 and Cardiac Function 
 The primary effect of PDE5 activity is to hydrolyze cGMP and thus lower its 
intracellular levels.  In turn, cGMP can influence other PDEs responsible for regulating 
cAMP by binding to their allosteric or catalytic sites.  Phosphodiesterase type 2 (PDE2) is 
expressed in myocytes and has regulatory GAF domains that can bind cGMP and in turn 
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enhance cAMP hydrolysis.75,76  Alternatively, cGMP can competitively bind to the 
catalytic site of phosphodiesterase type 3 (PDE3).  This enzyme binds both cAMP and 
cGMP at high affinity and similar Km but has a Vmax for cAMP 10-fold greater, conferring 
catalytic specificity.  At higher levels cGMP may inhibit PDE3 hydrolysis, resulting in 
enhanced cAMP which influences cardiac rhythm (chronotropy), contractile force 
(inotropy) and relaxation (lusitropy) while additionally playing a role in platelet 
aggregation and endothelial cell permeability (Fig. 2).77-81 
Still, of vital importance is cGMP’s ability to stimulate PKG and this is presently 
thought to be the major effect of PDE5 activity on vessels and the heart.  As previously 
mentioned, the classical role of PDE5 is in modulation of vascular smooth muscle 
contraction.  In this case, cGMP is generated either from soluble guanylate cyclase (sGC) 
present in the cytosol (triggered by NO) or from particulate guanylate cyclase (pGC) 
present at the plasma membrane (triggerd by NP).  The generated cGMP activates PKG 
which then via several mechanisms causes muscle relaxation.  These mechanisms involve 
decreasing intracellular free calcium concentrations,82,83 reducing calcium sensitization,84-
86 and regulating thin filament proteins (Fig. 1).87-94  Thus PDE5 functions, by catalyzing 
the hydrolysis of cGMP, to antagonize all of these observed effects and intriguing 
emerging evidence is beginning to show this role may be more significant in cardiac 
function than originally considered. 
The presence of PDE5 within the heart has been a contentious issue with many 
positive and negative findings.95-100  Our laboratory was able to detect PDE5 gene and 
protein expression in the mouse heart and cardiomyocytes by RT-PCR, immunofluorescent 
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staining, and Western blotting.43  Still, despite this discovery combined with other early 
evidence of myocardial PDE5 gene expression,69,101 its protein synthesis and enzyme 
activity are rather low compared with other tissues such as lung, and were traditionally 
thought to be physiologically insignificant.99,102  In spite of this, more recent studies have 
reported evidence of both detectable PDE5 mRNA and protein expression in isolated 
cardiomyocytes, as well as the physiologic effects of PDE5 inhibition in myocytes and 
whole heart.43,96,97,103  There is also growing evidence indicating the importance of 
compartmentation in cyclic nucleotide PDE modulation.104  Myocytes transfected with a 
cGMP-sensitive Ca2+ reporter channel recorded increased membrane cGMP induced by NP 
stimulation that was completely unchanged by concomitant PDE5 inhibition.  This 
contrasted to the signal generated by NO donors, which sildenafil enhanced.105   Therefore, 
it seems that PDE5 exerts a specific spatiotemporal control on the pool of intracellular 
cGMP synthesized by sGC but not that generated by pGC.  Additionally, although the 
levels of PDE5 in cardiomyocytes are rather low, newer data suggest its regulatory effects 
may be due to it being primarily localized to the Z-line in healthy animals, while under 
pathological conditions it is dispersed throughout the cell.43,96,103,106 
The level of PDE5 within the heart appears to be influenced by the occurrence of 
heart disease and it confers targeted regulation of stress responses despite having little 
influence on basal function.  PDE5 expression is reportedly increased in human and animal 
models of right ventricular hypertrophy.107  In these studies, PDE5 inhibition significantly 
increased contractility, cGMP, and cAMP in hypertrophied right ventricles but not in 
normal right ventricles.  Studies have also shown that cGMP catabolism by PDE5 is 
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increased in chamber and myocyte hypertrophy which can be suppressed by the 
administration of PDE5 inhibitors.108  Increased PDE5 expression has also been shown in 
left ventricles of humans with end-stage ischemic and dilated cardiomyopathy. 109,110  
These studies additionally demonstrated that a cardiomyocyte-specific overexpression of 
PDE5 in transgenic mice predominately localized to Z-bands and predisposed them to 
adverse left ventricle remodeling following AMI.  Along these same lines, it has been 
reported that myocyte hypertrophy is blunted by PDE5 gene silencing with small hairpin 
RNA (shRNA).106  PDE5 upregulation has also been cited in a number of other chronic 
cardiovascular diseases including pulmonary hypertension and congestive heart 
failure.111,112  Still, pathological regulation over PDE5 is scantily dealt with in the existing 
literature and its behavior has not been studied in more acute models of heart disease like 
I/R. 
 
1.6 PDE5 and Reactive Oxygen Species 
Aerobic organisms create energy needed to fuel biological functions by oxidative 
phosphorylation, a process which involves the transport of hydrogen ions across the inner 
mitochondrial membrane by means of the electron transport chain.  In the electron 
transport chain, electrons are passed through a series of proteins via redox reactions.  The 
last destination for an electron along this chain is an oxygen molecule.  Normally the 
oxygen is reduced to produce water, but sometimes oxygen is instead prematurely and 
incompletely reduced to create reactive oxygen species (ROS) such as superoxide radicals 
(·O2-) and hydrogen peroxide (H2O2).113-117  This "physiologic" generation of ROS is 
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normally inactivated by endogenous antioxidant scavenger mechanisms present within the 
cells.118   
During ischemia, ROS are generated within and can lead to damage to the electron 
transport chain of mitochondria.119-121  Upon reperfusion, with the return of oxygen, a large 
burst of ROS is seen.122-124  This increase in ROS during ischemia and reperfusion is 
thought to be due to damage to electron transport chain components resulting in inefficient 
transfer of electrons.  This toxic ROS overproduction can damage or deplete endogenous 
antioxidants and possibly contribute to irreversible damage of mitochondrial function and 
consequently impaired recovery of physiological function and cell death.125-130 
Recent studies have led to consideration of a correlation between ROS and PDE5 
expression/activity.  It has been demonstrated that exposing fetal pulmonary artery smooth 
muscle cells (FPASMCs) to hyperoxia leads to a decreased intracellular cGMP response, 
increased PDE5 phosphorylation, mRNA and protein expression, as well as increased 
cGMP hydrolytic activity.  Treatment of normoxic FPASMCs with exogenous H2O2 
induced PDE5 expression and activity, suggesting that ROS potentially mediate the PDE5-
enhancing effects of hyperoxia in FPASMCs.  Additionally, treatment with a chemical 
antioxidant, N-acetyl-cysteine, was sufficient to block the increases in PDE5 expression 
and activity.131  An extremely current work has shown that in mice, following transverse 
aortic constriction (TAC)-induced congestive heart failure (CHF), an increase of 
myocardial PDE5 expression positively correlated with the levels of oxidative stress 
markers 3’-nitrotyrosine and 4-hydroxynonenal expression.  The superoxide dismutase 
(SOD) mimetic M40401 attenuated oxidative stress and blunted PDE5 expression and 
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activity as well as CHF, while increased oxidative stress in SOD3 knockout mice 
exacerbated the increase in PDE5 expression and CHF following TAC.110  These studies 
are intriguing and lend credence to the possibility that oxidative stress could regulate PDE5 
within the heart. 
 
1.7 Rationale of the Present Study 
The purpose of the current investigation was to identify the role of PDE5 within the 
heart and specifically its response to acute cardiac I/R injury.  We hypothesized that the 
detrimental events of ischemia and reperfusion lead to a deleterious upregulation of PDE5, 
which is connected to the overproduction of ROS and contributes to the adverse cardiac 
stress response and pathological changes following AMI.  Of particular interest was 
defining PDE5 within the signaling mechanisms underlying the already proven 
cardioproctective action of selective PDE5 inhibitors. 
To test this hypothesis we used a murine model of in vivo regional I/R where we 
occluded the left anterior descending coronary artery (LAD) for 30 minutes and reperfused 
the heart for varying durations of time.  We additionally used a Langendorff isolated 
perfused mouse heart model to administer 30 minutes of global ischemia and varying 
durations of reperfusion.  This ex vivo model also allowed us to examine the effects of 
exogenous oxidant stress upon the heart via perfusion with the oxygen radical generator 
H2O2. 
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Figure 1: General scheme for the role of PDE5 in cGMP-signaling pathways. 
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Figure 2: Overview of PDE5 in cardiac muscle. 
Inhibition of PDE5 leads to a rise in intracellular cGMP and activation of PKG.  This may 
result in muscle relaxation and antihypertrophic effects.  The rise in cGMP may potentiate 
cAMP-mediated signaling in cardiac muscle by inhibition of PDE3 or reduce cAMP-
mediated signaling by stimulation of PDE2 
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Materials and Methods 
 
2.1 Animals 
Adult male ICR mice weighing 35.5 ± 1.2 g were supplied by Harlan Sprague 
Dawley Co. (Indianapolis, IN).  All animal experimental preparations and protocols were 
conducted under the guidelines on humane use and care of laboratory animals for 
biomedical research published by the U.S. National Institutes of Health (NIH Publication 
No. 85-23, revised 1996). The experimental protocols were approved by the Institutional 
Animal Care and Use Committee of Virginia Commonwealth University. 
 
2.2 Drugs and chemicals   
Unless otherwise specified, all the chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO).  Chemicals include those for preparing the K-H buffer in Langendorff 
isolated heart experiments (i.e. NaCl, NaHCO3, CaCl2, KCL, KH2PO4, MgSO4, glucose, 
EDTA) as well as H2O2.  Sildenafil is a pure solid powder and was kindly provided by 
Pfizer, Inc. (New York, NY) and dissolved in water.  Pentobarbital sodium was the 
anesthetic used for all the surgeries and was supplied by Ovation Pharmaceuticals, Inc. 
(Deerfield, IL). 
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2.3 Myocardial Infarction 
Prior to surgery, adult ICR mice were weighed and anesthetized with pentobarbital sodium 
(70 mg/kg, ip).  They were intubated orotracheally and ventilated on a positive-pressure 
rodent ventilator (Harvard apparatus), set at 133 cycles/min and a tidal volume of 0.2 ml.  
A left thoracotomy was performed at the fourth intercostal space in order to expose the 
heart.  Upon visualizing the LAD under a magnifier or microscope, a 7.0 silk ligature was 
passed underneath the artery and a piece of polyethylene (PE)-10 tubing was placed on the 
artery.  Ischemia was induced by tying the PE-10 tubing onto the artery with the ligature.  
The tubing was removed after 30 minutes of ischemia in order to reperfuse the vessel and 
the silk ligature was left in place to mark the risk area for ischemia.  A 5.0 silk suture was 
used to close the chest.  The animals were extubated and injected intramuscularly with 
analgesic (Buprenex; 0.02 mg/kg) for pain reduction, and antibiotic (gentamicin; 0.7 
mg/kg) to prevent infection.  Afterward, the animals were allowed to recover.  Following 
the desired length of reperfusion each mouse was again anesthetized with pentobarbital 
sodium (100 mg/kg, ip).  The chest was then opened at the sternum, and the heart was 
rapidly removed from the thorax and harvested at the different time points (Fig. 3).  The 
hearts were rinsed in PBS to remove blood, snap frozen in liquid nitrogen, and 
immediately stored in -80°C conditions until further use for biochemical/molecular assays. 
 
2.4 Measurement of infarct size 
Results were obtained from my lab group involving the use of PDE5 inhibitors and their 
effect on the subsequent infarct size following ligation.  Directly relevant to this project 
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was the protocol in which adult ICR mice received an injection of saline (0.2 mL, ip) or 
sildenafil (0.71 mg/kg in 0.2 mL saline, ip) 1 hour before undergoing 30 minutes of 
ischemia followed by 24 hours of reperfusion (Fig. 4).  At the end of each experiment, the 
hearts were washed of blood, and ~2 mL of 10% Evans blue dye was injected as a bolus 
into the aorta until most of the heart turned blue.  The heart was then washed with saline to 
remove the excess Evans blue.  Finally, the heart was frozen at -20°C.  The frozen hearts 
were then cut by hand using a surgical blade parallel to the atrioventricular groove, into 6 
to 8 transverse slices of approximately equal thickness (~1mm).  The heart slices were 
incubated in a 10% 2, 3, 5-triphenyl tetrazolium chloride (TTC, Sigma) solution for 30 
minutes at room temperature.  In normal myocardium, TTC is converted by dehydrogenase 
enzyme to a dark red formazan pigment.  On the other hand, infracted myocardium, due to 
loss of dehydrogenase enzyme following cell membrane rupture, does not take up TTC 
stain and remains a pale color.  After staining, the TTC was removed and replaced with 
10% formaldehyde for additional 2-4 hours to fix the heart slices.  Thereafter, the heart 
slices were digitally imaged and the areas of infarcted tissue, the risk zone, and the whole 
left ventricle were measured using computer morphometry (Bioquant98).  The risk area 
was calculated as total ventricular area minus the area of the cavities.  The infarct size was 
calculated as a percentage of the risk area (Fig. 5). 
 
2.5 Langendorff isolated heart preparation 
Prior to surgery, adult ICR mice were weighed and anesthetized deeply with pentobarbital 
sodium.  Anesthesia was prepared by mixing 0.2 mL of heparin to protect the heart against 
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microthrombi, 0.4mL of pentobarbital, and 0.2 mL saline.  Each mouse was injected 
intraperitoneally with 0.2 mL of anesthesia (100 mg/kg).  The chest was then opened at the 
sternum, and the heart was rapidly removed from the thorax and placed in a small dish 
containing ice-cold Krebs-Henseleit (K-H) buffer and heparin (0.1 mL per dish), where it 
was trimmed of excessive tissue and fat.  The aortic opening was exposed and quickly 
cannulated on a 20-gauge blunt needle and double loop tied using a 5.0 silk suture.  The 
heart was then retrogradely perfused at a constant pressure of 55 mmHg through the aorta 
in a non-recirculating Langendorff apparatus (Fig. 6) with modified K-H buffer [containing 
(in mM) 118 NaCl, 24 NaHCO3, 2.5 CaCl2, 4.7 KCL, 1.2 KH2PO4, 1.2 MgSO4, 11 
glucose, and 0.5 EDTA].  The K-H solution was pre-filtered by a micro-filter (Millipore 
Corp.) with a pore size of 0.45 μm diameter, and was continuously gassed with 95% O2 + 
5% CO2 (pH ~ 7.4).  The perfusion solution was warmed to 40 ºC through a water-jacketed 
glass cylinder/heat exchanger system with a warming/cooling bath and automatic thermal 
controller (Brinkmann) and was constantly circulated by a varistaltic water pump 
(Manostat).  The solution was warmed to 40 ºC to compensate for any heat loss 
experienced as the buffer circulates through the Langendorff apparatus.  The ambient 
temperature around the heart was also kept at 37 ± 0.2 ºC throughout the experiment using 
a 100 Watt heating lamp.  A digital thermometer (VWR) continuously monitored the air 
temperature around the heart.  Hearts were retrogradely perfused for the control, ischemia 
alone, or ischemia plus reperfusion groups at the different time points shown (Fig. 7).  For 
ischemia and reperfusion, following the 30 minute stabilization period, the hearts were 
subjected to a 30 minute no-flow normothermic global ischemia by closing off a stopcock 
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connected to the aortic cannula and reperfusion was started by reopening the stopcock of 
the aortic cannula and continued for 30 minutes.  In separate experiments, H2O2 (100 µM) 
was administered for 10 or 30 minutes via a syringe pump to the heart in conjunction with 
K-H buffer (Fig. 8).  Following 20 and 30 minute stabilization periods, respectively, the 
hearts were subjected to H2O2 perfusion by opening a side-port of the stopcock connected 
to the aortic cannula.  Once the appropriate time (10 or 30 minutes) of infusion had been 
achieved the stopcock was switched back to perfusion solely with K-H buffer for 30 
minutes.  Following treatment in both experiments, the hearts were then cut off of the 
Langendorff apparatus removing the atria, and snap frozen in liquid nitrogen and 
immediately stored in -80°C conditions until further use. 
 
2.6 Protein extraction 
Adult ICR mice hearts were snap frozen in liquid nitrogen and immediately stored at –
80°C following both myocardial infarction and Langendorff isolated heart protocols.  Each 
heart sample was crushed using a mortar and pestle. Liquid nitrogen was added as needed 
during this process to prevent the tissue sample from thawing.  Once the sample was 
crushed into a fine powder, 1.0 mL of ice-cold lysis buffer [containing (in mM) 20 Tris* 
HCL pH 7.4, 150 NaCl, 1 EDTA, 1 EGTA, 0.2 PMSF, 0.2 Na3VO4, and 5 β-
Mercaptoethanol, with protease inhibitor cocktail (Pierce) and phosphatase inhibitor 
cocktail (Pierce) (10 μL of each inhibitor per mL of buffer used)] was added to each 
sample tube.  The samples were then homogenized with a Glas-Col® Tissue Homogenizing 
System, transferred to Eppendorff tubes, and sonicated with a Heat Systems Inc. Sonicator 
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Ultrasonic Processor XL.  Each sample was kept on ice for an additional 30 minutes before 
being centrifuged at 12,000 G (Eppendorf Centrifuge 5810R) at 4°C for 15 minutes.  The 
supernatant was separated from the pellet, divided up into 3 aliquots, purified over Zeba 
Desalting Spin Columns (Thermo Fisher Scientific, Rockford, IL) and stored in –80°C 
conditions for further analysis.  Protein content of each heart sample was determined by 
using 10 mg of bovine serum albumin (BSA, Sigma-Aldrich) in 10mL of distilled water, 
forming a BSA stock solution.  Taking 1 mL of the solution and adding it to 19 mL of 
distilled water diluted this stock solution.  This second solution was used to establish a 
standard curve by adding different amounts of the BSA solution, water and protein assay 
dye (Bio-Rad Laboratories, Inc., Hercules, CA).  To determine the protein concentration of 
our collected samples, 2 μl of each heart tissue sample were added to 798 μl of water along 
with 200 μl of protein assay dye before protein concentration was determined by 
performing the Bradford assay using a SmartSpecTM 3000 spectrophotometer (Bio-
Rad).132 
 
2.7 Western Blot 
Protein samples were combined with an equal volume of a loading buffer solution made by 
mixing 25 μl of Laemmli sample buffer (Bio-Rad), and 475 μl β-mercaptoethanol (Bio-
Rad).  The samples were boiled for 5 minutes and centrifuged for 20 seconds at 14,000 
rpm at room temperature before being loaded into each well on polyacrylamide gels (Bio-
Rad).  A protein marker (Bio-Rad) was also used for better identifying the molecular 
weight of the target protein.  The gels were electrophoresed by a Bio-Rad energy pack for 
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1 hour at 180 volts using a running buffer [1X Tris/glycine/sodium dodecyl sulfide (TGS)].  
These electrophoresed proteins were trans-blotted from the gel to nitrocellulose 
membranes (Bio-Rad) for 90 minutes at 400 mA in 4°C using a transfer buffer (700 mL 
water, 200 mL methanol, 100 mL 10X TGS).  After transfer, the nitrocellulose membranes 
were placed for 1 hour in blocking solution [5% nonfat dry milk (Bio-Rad), in 1X Tris-
buffered saline (Bio-Rad) and 0.05% Tween-20 (Bio-Rad) wash (1X TBST)] at room 
temperature to inhibit nonspecific binding.  Subsequently, the membranes were incubated 
with primary antibodies on a rocking platform overnight in a 4°C cold room at the 
appropriate dilution in 5% milk in 1XTBST (1:500 for PDE5A [rabbit polyclonal] [Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA], 1:1000 for α-Tubulin [goat polyclonal] [Santa 
Cruz], 1:500 for phosphorylated-vasodilator-stimulated phosphoprotein [pVASP][Ser239] 
[rabbit polyclonal] [Cell Signaling Technology, Inc., Boston, MA], 1:500 for 
phosphorylated-phosphodiesterase type 5 [pPDE5][Ser92] [rabbit polyclonal] [Fabgennix, 
Inc., Frisco, TX], and 1:1000 for vasodilator-stimulated phosphoprotein [VASP] [rabbit 
polyclonal] [Cell Signaling]).  After being washed, the blots were incubated with anti-
rabbit (GE Healthcare, Buckinghamshire, UK) or anti-goat (Santa Cruz) secondary 
antibody conjugated to horseradish peroxidase at a 1:2000 dilution in 5% milk in 1XTBST 
on a rocking platform for 1 hour at room temperature.  Membranes were then washed, and 
the bands were visualized via enhanced chemiluminescence (PerkinElmer, Waltham, MA) 
and film in a dark room which was subsequently developed by a film processor (Kodak, 
Rochester, NY).  The bands of proteins were quantified using the Image J (Image 
Processing and Analysis in Java) computer program.  Expression for PDE5 and pPDE5 
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were normalized to α-Tubulin expression while expression for pVASP was normalized to 
VASP expression. 
 
2.8 Activity Assay 
Protein samples were assayed for cGMP hydrolytic activity using a commercially available 
spectrophotometric cyclic nucleotide phosphodiesterase assay kit (Biomol, Plymouth 
Meeting, PA).  The basis for the assay is the cleavage of cGMP by a cyclic nucleotide 
phosphodiesterase, such as PDE5, followed by the release of free phosphate by a 5’-
nucleotidase from Crotalus atrox venom.  The free phosphate is quantified using the 
Biomol Green reagent (Biomol) in a modified Malachite Green assay.133,134  The reactions 
were mixed in a 96-well plate, and started in a timed fashion by addition of 
phosphodiesterase.  Each sample was read in four wells, two without sildenafil and two 
with sildenafil (250 nM), to determine PDE5 specific cGMP hydrolytic activity.  The 
samples were then incubated at 30°C for 30 minutes and stopped in a timed fashion by 
addition of the Biomol Green reagent (Biomol).  The samples were incubated with the 
Biomol Green reagent at room temperature for 20 minutes.  Results were measured using a 
SpectraMax Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA) at 620 
nm wavelength and compared to a standard curve generated with GMP and 5’-
nucleotidase.  The difference between the pmol cGMP hydrolyzed per µg total protein per 
minute without sildenafil and the pmol cGMP hydrolyzed per µg total protein per minute 
with sildenafil represents the PDE5 specific cGMP hydrolytic activity.  Results are shown 
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as the PDE5 specific pmol cGMP hydrolyzed per µg total protein per minute for each 
sample.   
 
2.9 Cytotoxicity Assay 
In the Langendorff isolated heart preparations, the leakage of lactate dehydrogenase (LDH) 
into the isolated mouse heart coronary effluent was assayed spectrophotometrically using a 
commercially available kit (BioVision, Mountain View, CA).  The intracellular enzyme 
LDH is a stable cytoplasmic enzyme present in all cells and is rapidly released upon 
damage to the plasma membrane.  The basis for the assay is a coupled enzymatic reaction 
whereby LDH oxidizes lactate to pyruvate which then reacts with tetrazolium salt to form 
formazan which can be quantified by a formazan dye.  Thus the increase in the amount of 
formazan produced directly correlates to the increase in the number of lysed cells and 
functions as a way of monitoring cardiomyocyte death.  The coronary effluent was 
collected from the hearts at 1 minute prior to the global ischemia or H2O2 as well as 5, 10, 
20, and 30 minutes during the reperfusion period (Fig. 7 & 8).  The reactions were mixed 
in a 96-well plate, and started in a timed fashion by addition of 100µL of reaction mixture 
to 100µL of coronary effluent.  Each sample was prepared in duplicate and incubated at 
room temperature for 30 minutes while being protected from light.  Results were measured 
using a SpectraMax Multi-Mode Microplate Reader (Molecular Devices, Sunnyvale, CA) 
at 490 nm wavelength and normalized against the individual coronary flow rate. 
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2.10 Data analysis and statistics 
For each experiment, data from samples were calculated and expressed as means ± SEM.  
The significance of differences between experimental conditions was determined by 
unpaired t-tests.  P < 0.05 was considered to be statistically significant. 
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Figure 3: Myocardial infarction protocol for ischemia and I/R. 
Experimental protocol for studies of PDE5 following Ischemia and I/R.  Arrows indicate 
the time points for performance of surgical procedures. 
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Figure 4: Protocol for studies of sildenafil therapy on myocardial infarction. 
Experimental protocol for sildenafil administration prior to myocardial infarction.  
Sildenafil (0.71 mg/kg) was administered intraperitoneally 1 hour before left anterior 
descending coronary aretery (LAD) ligation.  Arrows indicate the time points for 
saline/sildenafil treatment and performance of surgical procedures. 
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Figure 5: Representative section of mouse heart. 
This cross section shows the criteria used to determine the risk area, non-risk area, 
infracted tissue, cavity area, and viable tissue.  The risk area was calculated as total 
ventricular area minus the area of the cavities.  The infarct size was calculated as a 
percentage of the risk area. 
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Figure 6: Illustrative description of the Langendorff isolated perfused heart system. 
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Figure 7: Langendorff isolated heart protocol for ischemia and I/R. 
Experimental protocol for studies of PDE5 following ischemia and I/R.  Arrows indicate 
the time points for performance of surgical procedures and minute marks show time points 
for collection of coronary effluent. 
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Figure 8: Langendorff isolated heart protocol for oxidant stress with 100 µM H2O2. 
Experimental protocol for studies of PDE5 following 10 minutes (A) or 30 minutes (B) of 
oxidant stress by perfusion with the oxygen radical generator H2O2.  Arrows indicate the 
time points for performance of surgical procedures and minute marks show time points for 
collection of coronary effluent. 
B 
A 
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Results 
 
3.1 Exclusions 
Among the hearts used in the experimental protocols, approximately 25% were 
excluded due to one or more of the following reasons: death during any portion of the 
surgical procedure, damage to the aorta during cannulation, longer cannulation time 
(greater than 3 minutes), excessive coronary flow, and arrhythmic heart beat during the 
stabilization period. 
 
3.2 Infarct size following Sildenafil preconditioning  
The selective PDE5 inhibitor sildenafil has been shown to have a cardioprotective 
effect in the mouse heart model by results obtained from my lab group.  Mice were divided 
into two experimental groups and sextuplicate samples were obtained following the 
surgical protocol for saline or sildenafil treatment, respectively (Fig. 4).  Myocardial 
infarct size was significantly reduced from 41.8±1.5% in saline-treated control mice to 
15.8±1.3% in sildenafil-treated mice (Fig. 9A, Fig. 10A & B).  Infarct size was calculated 
as a percentage of total risk area, a measured area that did not vary between the two 
experimental groups (Fig. 9B). 
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3.3 In vivo ischemia and I/R 
 Mice were divided into three experimental groups and triplicate samples of the 
whole heart were harvested following 30 minutes of ischemia, 30 minutes of ischemia plus 
12 hours reperfusion, or 30 minutes of ischemia plus 24 hours of reperfusion (Fig. 3).   
Cardiac PDE5 expression:  The expression of PDE5 was confirmed via Western blot 
analysis (Fig. 11).  All three treatment groups elicited a significant upregulation of PDE5 
protein when compared to their respective control sham operated groups (Fig. 12, Table 1).  
Interestingly, while this upregulation of PDE5 protein surged immediately following 30 
minutes of ischemia, there was a decrease at 12 hours of reperfusion followed by a 
subsequent increase at 24 hours of reperfusion (Fig. 13).   
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via 
spectrophotometric analysis.  All three treatment groups showed a trend towards increase 
in the activity of PDE5 enzyme when compared to the respective control sham operated 
group (Fig. 14, Table 1). 
Cardiac pPDE5 expression:  The expression of pPDE5 was confirmed via western blot 
analysis (Fig. 15).  After careful densitometry measurement of completed western blots, no 
appreciable difference in the phosphorylation state of PDE5 was observed between any of 
the time points (Fig. 16, Table 1).  
Cardiac pVASP expression:  The expression of pVASP was confirmed via western blot 
analysis (Fig. 17).  Densitometric scanning showed no appreciable difference in the 
phosphorylation state of VASP versus total VASP between any of the time points (Fig. 18, 
Table 1). 
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3.4 Ex vivo ischemia and I/R 
 Mice were divided into three experimental groups and quadruplicate samples of the 
whole heart were harvested following 90 minutes of normoxic perfusion, 30 minutes of 
global ischemia, or 30 minutes of global ischemia plus 30 minutes of reperfusion (Fig. 7).   
Cytotoxicity: The time course of LDH release into the coronary effluent during the pre-
ischemic stabalization and reperfusion periods was measured by spectrophotometric 
analysis.  Reperfusion of the isolated heart following ischemia caused a significant 
increase in the leakage of LDH (Fig. 19). 
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot 
analysis (Fig. 20).  The treatment groups elicited a significant increase in the upregulation 
of PDE5 protein when compared to their respective control of 90 minutes normoxic 
perfusion (Fig. 21, Table 1).  
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via 
spectrophotometric analysis.  Both treatment groups trended to increase in the activity of 
PDE5 enzyme when compared to the respective control normoxic perfusion group (Fig. 
22, Table 1). 
Cardiac pPDE5 expression:  The expression of pPDE5 was confirmed via western blot 
analysis (Fig. 23).  No appreciable difference in the phosphorylation state of PDE5 was 
observed between any of the time points (Fig. 24, Table 1). 
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot 
analysis (Fig. 25).  Interestingly, treatment of 30 minutes of global ischemia elicited a 
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significant increase in the upregulation of pVASP protein when compared to the respective 
normoxic perfusion, however no appreciable difference in the phosphorylation state of 
VASP versus total VASP was observed when the 30 minutes of global ischemia was 
followed by 30 minutes of reperfusion (Fig. 26, Table 1). 
 
3.5 10 minutes of ex vivo oxidant stress 
 Mice were divided into two experimental groups and sextuplicate samples of whole 
mouse heart were harvested following 60 minutes of normoxic perfusion or 10 minutes of 
perfusion with H2O2 plus 30 minutes of reperfusion (Fig. 8a).   
Cytotoxicity: The time course of LDH release into the coronary effluent during the 
stabalization and reperfusion periods was measured by spectrophotometric analysis.  
Perfusion of the isolated heart with H2O2 did not cause a significant increase in the leakage 
of LDH (Fig. 27). 
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot 
analysis (Fig. 28).  After careful densitometry measurement of completed western blots, no 
appreciable difference in the expression of PDE5 was observed (Fig. 29, Table 1).  
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via 
spectrophotometric analysis.  Oxidant stress had little effect on the activity of PDE5 
enzyme when compared to the respective control normoxic perfusion group (Fig. 30, Table 
1). 
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Cardiac pPDE5 expression:  The expression of pPDE5 was confirmed via western blot 
analysis (Fig. 31).  No appreciable difference in the phosphorylation state of PDE5 was 
observed between groups (Fig. 32, Table 1). 
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot 
analysis (Fig. 33).  After careful densitometry measurement of completed western blots, no 
appreciable difference in the expression of pVASP was observed (Fig. 34, Table 1). 
 
3.6 30 minutes of ex vivo oxidant stress 
 Mice were divided into two experimental groups and duplicate samples of whole 
hearts were harvested following 90 minutes of normoxic perfusion or 30 minutes of 
perfusion with H2O2 plus 30 minutes of reperfusion (Fig. 8b).   
Cytotoxicity: The time course of LDH release into the coronary effluent of isolated mouse 
hearts during the stabalization and reperfusion periods was measured by 
spectrophotometric analysis.  Perfusion of the isolated heart with H2O2 caused a significant 
increase in the leakage of LDH (Fig. 35). 
Cardiac PDE5 expression: The expression of PDE5 was confirmed via western blot 
analysis (Fig. 36).  Densitometric analysis of blots showed no appreciable difference in the 
expression of PDE5 (Fig. 37, Table 1).   
Cardiac PDE5 enzyme activity: The cGMP hydrolytic activity was confirmed via 
spectrophotometric analysis.  Oxidant stress had little effect on the activity of PDE5 
enzyme when compared to the respective control normoxic perfusion group (Fig. 38, Table 
1). 
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Cardiac pPDE5 expression:  The expression of pPDE5 was confirmed via western blot 
analysis (Fig. 39).  No appreciable difference in the phosphorylation state of PDE5 was 
observed between groups (Fig. 40, Table 1). 
Cardiac pVASP expression: The expression of pVASP was confirmed via western blot 
analysis (Fig. 41).  30 minutes of oxidant stress by H2O2 perfusion elicited a significant 
upregulation of pVASP protein expression when compared to the respective normoxic 
perfusion (Fig. 42, Table 1).   
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Figure 9: Sildenafil preconditioning reduces infarct size 
Adult male ICR mice were treated with either saline or sildenafil intraperitoneally 1 hour 
before being subjected to 30 minutes of left anterior descending coronary artery ligation 
followed by 24 hours of reperfusion.  Infarct size was significantly reduced by sildenafil 
(A), while risk area was calculated as a percentage of total area and was similar in both 
groups (B). 
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Figure 10: Representative digital images of stained heart slices 
Heart slices were stained with Evans blue dye, TTC, and fixed with formalin. Unaffected, 
non-risk area shows dark blue, viable risk area tissue remains red, and infarcted tissue 
appears pale white.  The saline control heart (A) has a much larger infarcted area when 
compared to the sildenafil-treated heart (B), which shows healthy myocardium and little 
infarcted tissue. 
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Figure 11: Ischemia and I/R upregulate cardiac expression of PDE5 in vivo   
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Following treatment hearts were harvested and equal amounts of whole 
heart homogenate protein were resolved by SDS-PAGE and analyzed by Western blotting 
with antibody against PDE5 (98 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to 
demonstrate equal protein loading. 
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Figure 12: Ischemia and I/R significantly increase cardiac PDE5 protein expression in 
vivo. 
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone(A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Western blot densitometry measurements were calculated as a ratio of 
PDE5 to α-Tubulin which is significantly increased by both ischemia and I/R when 
compared to respective sham controls.  Bar graphs represent the mean ± SEM. 
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Figure 13:  PDE5 protein expression varies with duration of reperfusion in vivo. 
In terms of the % increase from respective sham controls, the upregulation of PDE5 
protein peaked immediately following 30 minutes of ischemia, with a decrease at 12 hours 
of reperfusion followed by a subsequent increase at 24 hours of reperfusion. 
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Figure 14: Ischemia and I/R trend to increase cardiac PDE5 protein activity in vivo. 
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary artery 
ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of reperfusion (C).  
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity.  PDE5-
specific activity was measured as the sildenafil-inhibitable fraction of total cGMP hydrolysis, 
normalized for total micrograms of protein, and trends to increase with both ischemia and I/R when 
compared to the respective sham controls.  Results are shown as means ± SEM (n=3-4; read in 
duplicate). 
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Figure 15:  Ischemia and I/R do not affect cardiac pPDE5 expression in vivo.   
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Following treatment hearts were harvested and equal amounts of whole 
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting 
with antibody against pPDE5 (120 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to 
demonstrate equal protein loading. 
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Figure 16: Ischemia and I/R do not significantly affect cardiac pPDE5 protein 
expression in vivo. 
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Western blot densitometry measurements were calculated as a ratio of 
pPDE5 to α-Tubulin which is not significantly changed by either ischemia or I/R when 
compared to respective sham controls.  Bar graphs represent the mean ± SEM. 
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Figure 17:  Ischemia and I/R do not affect cardiac pVASP expression in vivo.   
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Following treatment hearts were harvested and equal amounts of whole 
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting 
with antibody against pVASP (48 kDa).  Blots were reprobed for total VASP (46 kDa) to 
ensure that any changes in phosphorylation of VASP were not due to changes in its total 
protein levels. 
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Figure 18: Ischemia and I/R do not significantly affect cardiac pVASP protein 
expression in vivo. 
Adult male ICR mice were subjected to 30 minutes of left anterior descending coronary 
artery ligation alone (A), or followed by 12 hours of reperfusion (B), or 24 hours of 
reperfusion (C).  Western blot densitometry measurements were calculated as a ratio of 
pVASP to total VASP which is not significantly changed by either ischemia or I/R when 
compared to respective sham controls.  Bar graphs represent the mean ± SEM. 
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Figure 19: Leakage of intracellular LDH due to I/R. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes 
of reperfusion.  Leakage of LDH in heart effluent perfusate was measured before and after 
the 30 minutes of global ischemia (except in the case of ischemia treatment alone, which 
by definition lacks reperfusion measurement).  Measurements of LDH activity were done 
spectrophotometrically using a commercially available enzyme assay kit at 490 nm 
wavelength (expressed as arbitrary unit, a.u./mL) and normalized against the individual 
coronary flow rate (mL/min).  Reperfusion of the isolated heart following ischemia caused 
a significant increase in the leakage of LDH.   Results are shown as means ± SEM. 
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Figure 20: Ischemia and I/R upregulate cardiac expression of PDE5 ex vivo.   
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, or 30 minutes of global zero-flow ischemia, or 30 minutes of global zero-flow 
ischemia plus 30 minutes of reperfusion in Langendorff mode.  Following treatment hearts 
were harvested and equal amounts of whole heart homogenate protein were resolved by 
SDS-PAGE and analyzed by Western blotting with antibody against PDE5 (98 kDa).  
Blots were reprobed for α-Tubulin (55 kDa) to demonstrate equal protein loading. 
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Figure 21: Ischemia and I/R significantly increase cardiac PDE5 protein expression 
ex vivo. 
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes 
of reperfusion.  Western blot densitometry measurements were calculated as a ratio of 
PDE5 to α-Tubulin which is significantly increased by both ischemia and 
ischemia/reperfusion when compared to respective normoxic perfusion controls.  Bar 
graphs represent the mean ± SEM. 
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Figure 22: Ischemia and I/R trend to increase cardiac PDE5 protein activity ex vivo. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes 
of reperfusion.  Hearts were harvested for total protein which was assayed for cGMP 
hydrolytic activity.  PDE5-specific activity was measured as the sildenafil-inhibitable 
fraction of total cGMP hydrolysis, normalized for total micrograms of protein, and trends 
to increase with both ischemia and reperfusion when compared to the respective control 
normoxic perfusion group.   Results are shown as means ± SEM (n=5; read in duplicate). 
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Figure 23:  Ischemia and I/R do not affect cardiac pPDE5 expression ex vivo.   
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes 
of reperfusion.  Following treatment hearts were harvested and equal amounts of whole 
heart homogenate protein were resolved by SDS-PAGE and analyzed by western blotting 
with antibody against pPDE5 (120 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to 
demonstrate equal protein loading. 
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Figure 24: Ischemia and I/R do not significantly affect cardiac pPDE5 protein 
expression ex vivo. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, 30 minutes of global ischemia, or 30 minutes of global ischemia plus 30 minutes 
of reperfusion.  Western blot densitometry measurements were calculated as a ratio of 
pPDE5 to α-Tubulin which is not significantly changed by either ischemia or 
ischemia/reperfusion when compared to respective normoxic perfusion.  Bar graphs 
represent the mean ± SEM. 
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Figure 25: Ischemia upregulates expression of cardic pVASP ex vivo which is 
partially normalized by reperfusion. 
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic 
perfusion as a control, 30 minutes of global ischemia (A), or 30 minutes of global ischemia 
plus 30 minutes of reperfusion (B).  Following treatment hearts were harvested and equal 
amounts of whole heart homogenate protein were resolved by SDS-PAGE and analyzed by 
western blotting with antibody against pVASP (48 kDa).  Blots were reprobed for total 
VASP (46 kDa) to ensure that any changes in phosphorylation of VASP were not due to 
changes in its total protein levels. 
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Figure 26: Ischemia significantly increases cardiac pVASP protein expression ex vivo 
which is partially normalized by reperfusion. 
Adult male ICR mouse hearts were isolated and subjected to 90 minutes of normoxic 
perfusion as a control, 30 minutes of global ischemia (A), or 30 minutes of global ischemia 
plus 30 minutes of reperfusion (B).  Western blot densitometry measurements were 
calculated as a ratio of pVASP to total VASP which is significantly increased following 30 
minutes of ischemia when compared to respective normoxic perfusion (see Graph A).  This 
increase is partially abolished by 30 minutes of reperfusion (see Graph B).  Bar graphs 
represent the mean ± SEM. 
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Figure 27: Leakage of intracellular LDH due to 10 minutes of ex vivo oxidant stress 
with 100 µM H2O2 infusion. 
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion, or 10 minutes perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Leakage of LDH in heart effluent perfusate was measured before and after the 10 minutes 
of perfusion with H2O2.  Measurements of LDH activity were done spectrophotometrically 
using a commercially available enzyme assay kit at 490 nm wavelength (expressed as 
arbitrary unit, a.u./mL) and normalized against the individual coronary flow rate (mL/min).  
10 min of H2O2 infusion did not cause a significant increase in the leakage of LDH.   
Results are shown as means ± SEM. 
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Figure 28: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac expression of PDE5.   
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with the oxygen radical generator H2O2 (100 µM) 
followed by 30 minutes of washout normoxic perfusion.  Following treatment hearts were 
harvested and equal amounts of whole heart homogenate protein were resolved by SDS-
PAGE and analyzed by western blotting with antibody against PDE5 (98 kDa).  Blots were 
reprobed for α-Tubulin (55 kDa) to demonstrate equal protein loading. 
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Figure 29: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not 
significantly affect cardiac PDE5 protein expression. 
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of PDE5 to α-Tubulin 
which is not significantly changed following oxidant stress when compared to respective 
normoxic perfusion control.  Bar graphs represent the mean ± SEM. 
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Figure 30: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac PDE5 activity. 
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity.  
PDE5-specific activity was measured as the sildenafil-inhibitable fraction of total cGMP 
hydrolysis, normalized for total micrograms of protein, and is not changed when compared 
to the respective control normoxic perfusion group.  Results are shown as means ± SEM 
(n=6; read in duplicate). 
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Figure 31: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac expression of pPDE5.   
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Following treatment hearts were harvested and equal amounts of whole heart homogenate 
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody 
against pPDE5 (120 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to demonstrate 
equal protein loading. 
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Figure 32: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not 
significantly affect cardiac pPDE5 protein expression.  
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of pPDE5 to α-Tubulin 
which is not changed following oxidant stress when compared to respective normoxic 
perfusion controls.  Bar graphs represent the mean ± SEM. 
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Figure 33: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac expression of pVASP.   
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Following treatment hearts were harvested and equal amounts of whole heart homogenate 
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody 
against pVASP (48 kDa, upper band).  Blots were reprobed for total VASP (46 kDa) to 
ensure that any changes in phosphorylation of VASP were not due to changes in its total 
protein levels. 
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Figure 34: 10 minutes of ex vivo oxidant stress with 100 µM H2O2 does not 
significantly affect cardiac pVASP protein expression.  
Adult male ICR mice hearts were isolated and subjected to 60 minutes of normoxic 
perfusion or 10 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of pVASP to total 
VASP which is not changed following oxidant stress when compared to respective 
normoxic perfusion controls.  Bar graphs represent the mean ± SEM. 
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Figure 35: Leakage of intracellular LDH due to 30 minutes of ex vivo oxidant stress 
with 100 µM H2O2 infusion. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion, or 30 minutes perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Leakage of LDH in heart effluent perfusate was measured before and after the 30 minutes 
of perfusion with H2O2.  Measurements of LDH activity were done spectrophotometrically 
using a commercially available enzyme assay kit at 490 nm wavelength (expressed as 
arbitrary unit, a.u./mL) and normalized against the individual coronary flow rate (mL/min).  
30 min of H2O2 infusion caused a significant increase in the leakage of LDH.   Results are 
shown as means ± SEM. 
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Figure 36: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion does not 
affect expression of PDE5.   
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Following treatment hearts were harvested and equal amounts of whole heart homogenate 
protein were resolved by SDS-PAGE and analyzed by Western blotting with antibody 
against PDE5 (98 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to demonstrate equal 
loading. 
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Figure 37: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion does not 
significantly affect PDE5 protein expression. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of PDE5 to α-Tubulin 
which is not changed following oxidant stress when compared to respective normoxic 
perfusion controls.  Bar graphs represent the mean ± SEM. 
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Figure 38: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac PDE5 activity. 
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Hearts were harvested for total protein which was assayed for cGMP hydrolytic activity.  
PDE5-specific activity was measured as the sildenafil-inhibitable fraction of total cGMP 
hydrolysis, normalized for total micrograms of protein, and is not changed when compared 
to the respective control normoxic perfusion group.  Results are shown as means ± SEM 
(n=2; read in duplicate). 
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Figure 39: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not affect 
cardiac expression of pPDE5.   
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Following treatment hearts were harvested and equal amounts of whole heart homogenate 
protein were resolved by SDS-PAGE and analyzed by western blotting with antibody 
against pPDE5 (120 kDa).  Blots were reprobed for α-Tubulin (55 kDa) to demonstrate 
equal protein loading. 
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Figure 40: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 does not 
significantly affect cardiac pPDE5 protein expression.  
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of pPDE5 to α-Tubulin 
which is not changed following oxidant stress when compared to respective normoxic 
perfusion controls.  Bar graphs represent the mean ± SEM. 
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Figure 41: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion 
upregulates expression of pVASP.   
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Following treatment hearts were harvested and equal amounts of whole heart homogenate 
protein were resolved by SDS-PAGE and analyzed by Western blotting with antibody 
against pVASP (48 kDa).  Blots were reprobed for total VASP (46 kDa) to ensure that any 
changes in phosphorylation of VASP were not due to changes in its total protein levels. 
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Figure 42: 30 minutes of ex vivo oxidant stress with 100 µM H2O2 infusion 
significantly increases cardiac pVASP protein expression.   
Adult male ICR mice hearts were isolated and subjected to 90 minutes of normoxic 
perfusion or 30 minutes of perfusion with 100 µM H2O2 followed by 30 minutes washout.  
Western blot densitometry measurements were calculated as a ratio of pVASP to total 
VASP which is significantly increased following oxidant stress when compared to 
respective normoxic perfusion controls.  Bar graphs represent the mean ± SEM. 
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Experimental Protocol PDE5 
Expression
PDE5   
Activity 
pPDE5 
Expression
pVASP 
Expression
in vivo I/R   — — 
ex vivo I/R   —  
10 min. H2O2 — — — — 
30 min. H2O2 — — —  
 
 
Table 1: Summary of experimental results 
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Discussion 
 
4.1 Rationale of the Present Study 
The concept of pharmacological preconditioning with selective PDE5 inhibitors 
protecting the heart against I/R injury was first introduced by Ockaili et al. in 2002 from 
our laboratory.38  In that study and in a series of publications thereafter, our laboratory has 
shown that this preconditioning-like cardioprotective effect against I/R involved 
upregulation of eNOS and iNOS, activation of PKC/ERK, opening of mitochondrial KATP 
channels, and attenuation of apoptosis by increasing the Bcl2/bax ratio.38,39,41-43  Still, as 
diverse as these mechanisms are, none of these previous studies has shown a direct 
involvement of PDE5 or relate to the known pharmacological action of sildenafil on 
inhibiting PDE5.  The purpose of the current investigation was to identify the role of PDE5 
within the heart and specifically its response to cardiac ischemia/reperfusion injury.  We 
postulated that the detrimental events of ischemia and reperfusion lead to a deleterious 
upregulation of PDE5 which is connected to the production of ROS and contributes to the 
adverse cardiac stress response that follows myocardial infarction.  Of particular interest 
was defining PDE5 within the signaling mechanisms underlying the already proven 
cardioproctective action of selective PDE5 inhibitors. 
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4.2 Salient Findings 
The major findings of this study are summarized as follows:  1. In vivo regional 
ischemia and I/R increase the expression and trend to increase activity of PDE5 without 
affecting PKG activity.  2. Ex vivo global ischemia and I/R increase the expression and 
trend to increase activity of PDE5 as well as enhance PKG activity.  3. 10 minutes of ex 
vivo oxidant stress had little to no effect upon PDE5 expression and activity as well as 
PKG activity.  4. 30 minutes of ex vivo oxidant stress had little to no effect upon PDE5 
expression and activity yet raised PKG activity.  Taken together, these results provide the 
first evidence that in acute cardiac ischemia and I/R, PDE5 upregulation may contribute to 
a deleterious decline in cGMP and cytoprotective PKG signaling, potentially exacerbating 
dysfunction.  Additionally, there appears to be no connection between exposure to ROS 
and the induction of PDE5.  In fact, our data suggest two completely independent 
mechanisms where PKG is induced by high levels of oxidant stress and PDE5 is induced 
by the mediators other than ROS resulting from an ischemic event.   
While our in vivo model shows both ischemia and I/R upregulate PDE5 with 
downstream pVASP (an indicator of PKG activity) remaining unaltered, our ex vivo model 
contrastingly shows a similar PDE5 upregulation but with a concordant downstream 
increase in pVASP.  This initially may seem paradoxical or contradictory, but the results 
garnered from treatment with exogenous H2O2 lead to a logical explanation.  10 minutes of 
oxidant stress resulted in no change in either PDE5 or pVASP expression, whereas 30 
minutes of oxidant stress still resulted in no change in PDE5 but a dramatic increase in 
pVASP expression.  So, while low and high oxidant stress both had no effect on PDE5, it 
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is only the high level of ROS that had a significant impact on PKG.  Now the process 
becomes clearer with respect to the ischemia models.  In vivo, by ligation of the LAD, only 
approximately 30 to 40% of the cardiomyocytes undergo ischemia.  Ex vivo, the heart is 
subjected to global zero-flow ischemia, and by definition 100% of the cardiomyocytes 
undergo ischemia.  So we believe that what is being witnessed within each of the models 
can be considered under a “low” or “high” oxidant stress paradigm, respectively.  The 
lower number of ischemic cardiomyocytes in vivo produce less ROS leading to relatively 
low oxidant stress, having no effect on PKG.  The higher number of ischemic myocytes in 
the ex vivo model produce much more ROS leading to high oxidant stress, which activates 
PKG.  Lastly, while both the in vivo and ex vivo hearts exhibited the increased PDE5 in 
response to ischemia and I/R, neither low nor high levels of exogenous oxidant stress had 
any effect on PDE5.  Taken all together, this leads to the aforementioned speculation that 
the upregulation of PDE5 is likely triggered via other mediators or factors following 
ischemia and I/R, independent of exposure to the generated ROS (Fig. 43). 
Overall a pathogenic PDE5 upregulation during ischemia and I/R may have an 
important role in facilitating the acute stress response after AMI, as well as adverse 
remodeling and functional impairment.  Combined with data obtained from the previous 
studies published by our group proving that PDE5 inhibition prior to AMI leads to a 
dramatic reduction in infarct size in mice,39 these novel results mechanistically validate the 
therapeutic strategies to combat this pathogenic PDE5 upregulation with selective PDE5 
inhibitors. 
 
77 
4.3 Upregulation of PDE5 triggered by in vivo ischemia and I/R  
The presence of PDE5 within the heart has been a contentious issue with many 
positive and negative findings.95-100  Recently, our lab was able to detect PDE5 expression 
in the mouse heart and cardiomyocytes by RT-PCR, immunofluorescent staining, and 
Western Blotting.43  Still, despite this discovery combined with other evidence of 
myocardial PDE5 gene expression,69,101 its protein synthesis and enzyme activity are rather 
low compared with other tissues such as lung, and have been traditionally thought to be 
physiologically insignificant.99,102  In the current investigation, ICR mice underwent 
regional AMI by LAD ligation and the hearts were analyzed for PDE5, pPDE5 and pVASP 
expression as well as PDE5 activity.  All three treatment groups (i.e. 30 min ischemia 
alone, 30 min ischemia plus 12 hours or 24 hours of reperfusion) elicited a significant 
upregulation of PDE5 protein when compared to their respective control sham operated 
groups.  In addition, we observed this upregulation of PDE5 protein surged immediately 
following 30 minutes of ischemia, and there was a decrease at 12 hours of reperfusion 
followed by a subsequent increase at 24 hours of reperfusion (Fig. 12, Fig. 13, Table 1).  
This overall increase in PDE5 expression is scantily dealt with in the existing literature and 
the factors leading to its occurrence are both poorly understood and intriguing.  As stated 
previously, we initially hypothesized it may be related to the production of ROS created 
during ischemia and reperfusion, however our results suggest against this assumption 
(Section 4.5).  Still, ischemia and I/R injury set in motion a great number of signaling 
cascades that could potentially be responsible for the phenomenon we observed.  One 
compelling possibility is angiotensin II (AngII), which has been shown to rapidly increase 
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PDE5 mRNA and protein expression as well as PDE5 activity in vascular smooth 
muscles.135  AngII is a powerful vasoconstrictor peptide that is proven to be produced 
during ischemia.136-138  Furthermore, AngII can be produced endogenously in the heart.139  
Hence it is conceivable that activation of AngII may play a role in upregulation of PDE5 
and the resultant antagonization of cGMP signaling following myocardial ischemia.  
Additionally, PDE5 upregulation could instead be attributed to NP (such as atrial 
natriuretic peptide [ANP] and B-type natriuretic peptide [BNP]), which are known to be 
released in response to myocardial ischemia.  ANP and BNP levels are raised in patients in 
the early phase of AMI.140  This increase in NP would then lead to an increase in pGC 
activity, raising cGMP levels which then could cause PDE5 upregulation perhaps as a 
feedback countering mechanism to trigger its breakdown in an attempt to maintain cGMP 
levels within the physiological normal range in response to the insult of ischemia and I/R.  
Furthermore, PDE5 has been shown to be phosphorylated in response to ANP, 141 however 
this was not witnessed in our samples (Fig. 16, Table 1).  These increased PDE5 levels 
may relate to cGMP/PKG effects on transcription and posttranslational activation.  Yet, the 
increase we witnessed in PDE5 protein did not lead to an appreciable difference in 
downstream PKG signaling, as evidenced by an insignificant change in pVASP protein, 
whose phosphorylation is a direct product of PKG’s kinase activity (Fig. 18, Table 1).  The 
results additionally show that, while not significant, all three treatment groups trend to 
cause an increase in PDE5 enzymatic activity (Fig. 14, Table 1).  Thus, this clear 
demonstration of PDE5 upregulation following cardiac ischemia and I/R suggests it may 
contribute to a decline in cGMP and potential disruption of protective signaling in the 
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heart.  For example, PDE5 expression is reportedly increased in human and animal models 
of right ventricular hypertrophy.107  This elevation did not translate to enhanced PKG 
signaling when PDE5 inhibitors were applied.  Increased PDE5 expression has also been 
shown to predispose mice to adverse left ventricle remodeling after AMI.109 
 
4.4 Upregulation of PDE5 triggered by ex vivo ischemia and I/R 
In the current investigation, the hearts underwent ischemia and reperfusion in 
isolated perfused Langendorff mode.  The rationale for using the isolated heart model was 
to eliminate all circulating factors that exist in vivo and demonstrate the direct effect of 
ischemia and reperfusion on the expression and activity of PDE5 in the intact heart.  The 
hearts underwent global zero-flow ischemia and were analyzed for PDE5, pPDE5 and 
pVASP expression as well as PDE5 activity.  Both treatment groups (i.e. 30 min ischemia 
alone, or 30 min ischemia plus 30 minutes of reperfusion), elicited an upregulation of 
PDE5 protein when compared to their respective control 90 minutes of normoxic 
perfusion.  While both groups elicited an increase, the ischemia alone group yielded the 
greater upregulation, which agrees with our in vivo experiments (Fig. 21, Table 1).  
Interestingly, ischemia alone also concurrently increases downstream PKG signaling, as 
evidenced by the significant increase in cardiac pVASP protein expression, which is then 
partially normalized by subsequent reperfusion (Fig. 26, Table 1).  The results additionally 
show that both groups cause an increase in PDE5 enzymatic activity and suggest that, 
while not significant, the increase due to I/R is greater than the increase following ischemia 
alone (Fig. 22, Table 1).  At first, we postulated the concordant increase in both the PDE5 
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levels along with pVASP phosphorylation may be indicative of cGMP levels being 
regulated by a PKG-dependent activation of PDE5.  Specifically, an increase in cGMP 
levels leads to triggering its breakdown by PDE5.  At the same time, the activity of PDE5 
is enhanced by PKG-dependent phosphorylation initiated by cGMP-specific binding to 
allosteric sites on PDE5 in an attempt to maintain cGMP levels within the physiological 
normal range in response to the insult of ischemia and I/R.142  Yet this phosphorylation 
was not witnessed in our samples (Fig. 24, Table 1).  As mentioned previously, while we 
initially hypothesized that ROS production during ischemia and reperfusion may be related 
to the PDE5 upregulation witnessed, we now believe that this oxidant stress is actually 
directly affecting PKG independent of PDE5 upregulation.  In this model, a great deal of 
ROS are being produced by the global zero-flow ischemia of the Langendorff, whereby 
100% of the cardiomyocytes undergo ischemia.  We believe this high level of oxidant 
stress is directly activating PKG and causing the high levels of pVASP expression (Section 
4.5).  The partial normalization of pVASP expression following reperfusion is likely a 
result of washout of the ROS produced during ischemia and upon reperfusion. 
 
4.5 Effect of exposure to exogenous H2O2 on PDE5 
Heart ischemia is known to induce increased generation of ROS, and subsequent 
reperfusion can result in toxic ROS overproduction that possibly contributes to irreversible 
damage of mitochondrial function and consequently impaired recovery of physiological 
function and cell death.125-129  In the current investigation, the hearts underwent oxidant 
stress in isolated perfused Langendorff mode to demonstrate the direct effect of exposure 
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to ROS on the expression and activity of PDE5 in the intact heart without any circulating 
confounders that exist in vivo.  Following 10 minutes of perfusion with the oxygen radical 
generator H2O2 (100 µM) followed by 30 minutes of washout normoxic perfusion, the 
hearts were analyzed for PDE5, pPDE5 and pVASP expression as well as PDE5 activity.  
The results showed that 10 minutes of oxidant stress had little effect on the amount of 
PDE5 or pPDE5 protein when compared to the respective control 60 minutes of normoxic 
perfusion (Fig. 29, Fig. 31, & Table 1).  This same treatment also left downstream PKG 
signaling unaltered, as evidenced by the unaffected levels of cardiac pVASP protein 
expression (Fig. 34, Table 1).  The results further suggest that a short duration of ROS 
exposure results in little to no increase in PDE5 enzymatic activity (Fig. 30, Table 1).  
Some have purported a possible interaction between ROS and PDE5 may potentially lie in 
the fact that promoter analysis shows both a Sp-1 and an activator protein-1 (AP-1) site in 
the human PDE5 promoter region.143  Both of these transcription factors have been shown 
to be redox sensitive and are claimed to represent potential downstream targets of ROS-
mediated signaling on PDE5.144  However, they are also downstream targets of AngII as 
well and, as mentioned, this could be a potential mediator of PDE5 upregulation.  Farrow 
et al. have reported that treatment of FPASMCs with exogenous H2O2 leads to a significant 
upregulation of PDE5.131  Reconciling this with our results may lie in the models 
themselves.  Farrow et al. utilized isolated FPASMCs while we investigated adult whole 
heart homogenates.  Not only were entirely different cell types being studied, but it is 
possible that ROS have a much different effect on isolated cells when compared to 
exposure via intra-coronary perfusion of an entire organ.  Lu et al. have reported that 
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myocardial PDE5 expression is increased in CHF along with oxidative stress markers and 
that this increase is blunted by a SOD mimetic.110  However the approach in this study also 
differs greatly from our own.  Lu et al. implemented a protocol of chronic TAC induced 
CHF while we instead looked at the much more acute model of I/R and exogenous 
administration of H2O2.  Ultimately, ROS is a very general effecter of many transcription 
factors and the presence of Sp-1 and AP-1 promoter sites in the PDE5A gene does not 
implicate a direct connection.  Oxidative stress can broadly affect many signaling 
pathways by altering the expression and modification of many important molecules.  A 
precise molecular mechanism by which oxidative stress can regulate PDE5 expression has 
not been defined and our results indicate that such a potential link does not sufficiently 
lead to the induction of PDE5, and this induction instead occurs via other mediating factors 
independent of ROS.   
Further emphasizing this point, additional hearts were subjected to 30 minutes of 
H2O2 (100 µM) perfusion followed by 30 minutes of washout normoxic perfusion, and 
again analyzed for PDE5, pPDE5 and pVASP expression as well as PDE5 activity.  The 
longer duration of oxidant stress had little effect on the amount of PDE5 or pPDE5 protein 
when compared to the respective control 90 minutes of normoxic perfusion (Fig. 37, Fig. 
40, & Table 1).  However, this treatment did lead to an increase in downstream PKG 
signaling, as evidenced by the significantly higher levels of cardiac pVASP protein 
expression (Fig. 42, Table 1).  The results additionally suggested that a long duration of 
ROS exposure results in unchanged PDE5 enzymatic activity (Fig. 38, Table 1).  This 
result, given the longer exposure to oxidative stress, again underscores the lack of a 
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connection between ROS and PDE5.  However, there is a growing body of literature 
showing PKG is regulated by cellular redox status.145,146  In fact, it was recently shown that 
oxidation of PKG by exogenous H2O2 directly activated PKG and this oxidation-induced 
activation indicates an alternate mechanism for its regulation independent of the classical 
activation via cGMP.147  Thus, it is likely that the observed induction of PKG following 30 
minutes of oxidative stress is proceeding through this mechanism and it appears the 
oxidation-induced activation is time dependent with respect to exposure duration to H2O2, 
given that 10 minutes of oxidative stress produced little change in cardiac pVASP 
expression.   
 
4.6 Future Studies 
More work is needed to better elucidate the pathophysiologic conditions under 
which PDE5 upregulation occurs as well as the principal mediating factors involved (e.g. 
by using AngII receptor blockers). Additional investigations are also required to further 
demonstrate the lack of a relationship between ROS and PDE5.  This would be 
accomplished by monitoring PDE5 and pVASP levels following administration of 
antioxidants such as N-2-mercaptopropionyl glycine (MPG) to the hearts subjected to 
ischemia and I/R in the isolated perfused heart model.  According to our current theory, 
PKG activity would be blocked by antioxidants while PDE5 upregulation still present, 
providing a more definitive illustration of two separate mechanisms at work.  Furthermore, 
it would be highly valuable to reproduce the current results within isolated ventricular 
cardiomyocytes themselves to demonstrate the cell type specificity. 
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4.7 Conclusions and Translational Perspectives 
It is paramount to recognize that practicing preventative medicine will most 
effectively control the prevalence and persistence of heart disease and specifically 
myocardial infarction in our country.  However, limitations such as access, availability, 
education, and other socioeconomic factors of medical care often impair this approach.  
Therefore, a clinical challenge exists in finding therapeutic strategies to limit and reduce 
ischemic insult, thus preserving heart function.  Novel medical treatments that will 
effectively limit the extent of tissue damage caused by myocardial infarction are urgently 
needed.  Identifying mechanisms of endogenous cellular protection or tolerance against 
ischemia is coming to the forefront of research in order to find new methods for treating 
cardiovascular diseases.  This study acknowledges that fact and identifies PDE5 as a valid 
and novel target to combat the detrimental effects of a heart attack.   
Our present studies have provided the first evidence that cardiac PDE5 
upregulation, occurring as a result of infarction, is independent of oxidant stress and it may 
contribute to a deleterious decline in cGMP and a potential disruption of protective 
signaling in the ischemic heart.  The discovery of this pathogenic PDE5 upregulation that 
occurs following ischemia and I/R further augments and mechanistically validates the 
argument for therapeutic strategies utilizing selective PDE5 inhibitors in the fight against 
irreversible heart attack damage.  We have witnessed a seemingly ever growing pandemic 
of heart disease and heart attacks in our country today.  Often we are hard pressed to find 
anyone who has not had a relative or significant other affected by these diseases.  Yet the 
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observations contained within this study help in identifying a novel target for treatment and 
I am excited that amid growing interest combined with dedication, we may look forward to 
major strides being taken during our lifetime toward making sure further life is not lost. 
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Figure 43: Summary of ROS-independent upregulation of PDE5 in the ischemic 
heart. 
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